Does Mavorixafor Interact with Mao Inhibitors?
CDI records a major classification for Mavorixafor and Mao Inhibitors. The stored summary is: Concomitant use increases mavorixafor Cmax and AUC, increasing risk of adverse reactions. Requires dosage reduction to 200 mg daily. The mechanism involves inhibition of cyp3a4-mediated metabolism of mavorixafor. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Mavorixafor Class
- CXC Chemokine Receptor 4 Antagonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of CYP3A4-mediated metabolism of mavorixafor
What To Tell Your Doctor or Pharmacist
If you are taking Mavorixafor and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider